Calls
1
u/LowCommunication9778
Reddit r/pennystocks
Win Rate
0.0%
return
-79.5%
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Jan 15
$1.17
-79.5%
Author argues AEON Biopharma is undervalued because its pivot to the 351(k) biosimilar pathway for ABP-450 could let it prove it is 'highly similar' to Botox and potentially cover all of Botox's approved uses under one license, avoiding separate Phase 3 trials. The near-term catalyst is the January 21 BPD Type 2a FDA meeting on the sufficiency of its analytical package; a positive green light could trigger a re-rating. The author also cites Daewoong's mid-December conversion of $15 million debt into equity as a balance-sheet cleanup and signal before the catalyst. Main stated risk: the FDA may still require heavy, expensive comparative clinical trials that could outpace AEON's cash runway.
Other
Showing 1 of 1 calls · sorted by mentions
Choose a mentions count to open ticker posts.
u/LowCommunication9778 has 1 trade ideas tracked on Buzzberg across 1 tickers since January 2026. Most covered: AEON.
Historical call returns are modeled from recorded ideas and stored prices, not actual brokerage portfolio returns. Check the evaluated call set and horizon; past results do not establish future prediction accuracy. Explore our data and methodology
